Drug Target for Fragile X Syndrome Identified Through Preclinical Study
Researchers identified the synaptic protein EPAC2 as a potential therapeutic target for fragile X syndrome, and showed that blocking EPAC2 in an FXS mouse model restored abnormal patterns of brain activity and improved several FXS-associated behavioral symptoms. The post Drug Target for Fragile X Syndrome Identified Through Preclinical Study appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.